Summary

Australia's vaccine market is a dynamic and vital component of the nation's healthcare system. With a strong emphasis on preventive healthcare, Australia has consistently maintained high vaccination rates, protecting its population from a range of vaccine-preventable diseases. This article explores the key trends, challenges, and opportunities within the Australian vaccine market. Australia has a long history of successful vaccination programmes, resulting in high vaccination rates among children and adults. The country's robust immunisation schedule covers a wide range of diseases, including influenza, measles, mumps, rubella, and hepatitis. Australia is known for its active research and development in the field of vaccines. Local pharmaceutical companies, research institutions, and universities collaborate on vaccine development projects, contributing to global efforts. The Australian pharmaceutical industry collaborates with international partners, enhancing vaccine availability and access for the Australian population. Partnerships with global vaccine manufacturers strengthen the supply chain. Australia's strong international ties and a high rate of overseas travel drive demand for travel vaccines, including those for tropical diseases such as yellow fever and Japanese encephalitis. The COVID-19 pandemic has highlighted Australia's capacity to rapidly deploy vaccines. The successful management of the pandemic through vaccine distribution and administration showcases the country's healthcare capabilities. Australia's strong research capabilities present opportunities for further vaccine development, including those for emerging infectious diseases. Australia's active involvement in global health initiatives, including vaccine distribution to neighbouring countries, strengthens its role in the region.

According to the research report, "Australia Vaccines Market Outlook, 2028," published by Bonafide Research, the Australia Vaccines market is anticipated to add more than 600 Million from 2023–2028. Australia has a long-standing national immunisation programme that includes a variety of diseases that can be prevented by immunisation, from paediatric immunisations through adult immunisations against diseases including influenza and shingles. Vaccine demand is consistently increased by these programmes. The Australian government actively supports vaccination through funding, recommendations, and mandates. Government policies and initiatives play a crucial role in driving vaccine demand. Healthcare providers including doctors, nurses, and pharmacists, play a key role in counselling patients and recommending vaccines. Their expertise and guidance influence vaccine demand. Due to Australia's geographic location and international travel, there is a demand for travel vaccines to protect individuals travelling abroad from diseases prevalent in other regions. Vaccines administered as part of national vaccination programmes are typically covered by Australia's health insurance system, making them affordable for patients. Australia actively participates in global health initiatives and contributes to international vaccination efforts. This global perspective can influence domestic vaccine demand. Australia's ageing population drives demand for vaccines targeting diseases more common among older adults, such as influenza and pneumonia. Australia's healthcare system provides accessible healthcare services, including vaccination, to all citizens. This accessibility promotes vaccine demand and coverage. The country has a culture that emphasises preventive healthcare measures. Vaccination is seen as a proactive way to protect against diseases. Public health campaigns and educational programmes raise awareness about the importance of vaccination. These campaigns provide accurate information and dispel misconceptions, encouraging individuals to get vaccinated.

According to the report, the technology is segmented into conjugate vaccines, inactivated and subunit vaccines, live-attenuated vaccines, recombinant vaccines, and toxoid vaccines. In the country, the live-attenuated vaccines will grow with the highest capacity by the forecast year. Live-attenuated vaccines are well-known for their effectiveness in providing robust and enduring immunity against a range of infectious diseases. The proven track record of LAVs in conferring immunity with a single or a few doses makes them highly desirable. Australia maintains a comprehensive national immunisation programme that routinely incorporates live attenuated vaccines, such as the measles, mumps, and rubella (MMR) ccines. The consistent inclusion of these vaccines in the immunisation schedule ensures a steady and sustained demand. In scenarios of disease outbreaks, live attenuated vaccines can serve as essential tools for public health authorities to curb the spread of infectious diseases swiftly and effectively. Their role in outbreak control sustains demand. Live-attenuated vaccines are effective in preventing diseases like tuberculosis, yellow fever, retrovirus, measles, polio, and other ailments, which is predicted to fuel market expansion. The incidence of tropical infections is rising due to the prevalence of fungal illnesses worldwide, which is expected to boost the market for live-attenuated vaccines. Additionally, during the analysis period, the market participants have profitable potential due to the increase in demand for innovative treatments.

In terms of the end user segment, which includes adults and paediatrics, in Australia, paediatrics is the leading market. Australia has a robust National Immunisation Programme (NIP) that provides free vaccines to all eligible children. This programme includes a comprehensive schedule of vaccines, starting in infancy and continuing throughout childhood. It covers diseases like measles, mumps, rubella, diphtheria, pertussis, tetanus, and more. This consistent and well-established schedule ensures a high demand for paediatric vaccines. Australia has a high level of public trust in vaccines, including those administered to children. Parents generally have confidence in the safety and efficacy of paediatric vaccines. The Australian government actively supports vaccination programmes by providing funding, recommendations, and mandates. Government policies and initiatives are instrumental in driving vaccine demand among children. Australian parents typically prioritise the health and well-being of their children. Preventive healthcare measures, including vaccination, are considered essential for ensuring the long-term health of their children.

Based on the route of administration, they are segmented into intramuscular and subcutaneous administration, oral administration, and others. In the country, oral administration is a growing market. The introduction and approval of new oral vaccines targeting specific diseases may have led to an increase in the use of oral administration. Oral vaccines are particularly well-suited for diseases that enter the body through the gastrointestinal tract, such as rotavirus and polio. If these diseases are of concern in Australia, oral vaccines may be preferred. re Some oral vaccines are more stable at higher temperatures compared to injectable vaccines. This can be advantageous in regions with diverse climates and varying access to refrigeration. d. Public health campaigns and initiatives aimed at preventing specific diseases could include the use of oral vaccines. These campaigns may focus on specific populations, such as infants, for rotavirus vaccination. Oral vaccines are generally well-accepted, especially among children and individuals with a fear of needles. The convenience of oral administration can lead to higher vaccination rates. Government support and regulatory approvals play a crucial role in the growth of oral vaccines. The Australian government's commitment to public health and vaccination can facilitate the availability and use of these vaccines.

In terms of disease types, they include the rotavirus, pneumococcal diseases, cancer, influenza, diphtheria, pertussis, and tetanus, the human papilloma virus (HPV), hepatitis, shingles, meningococcal diseases, varicella, mumps, and others. In our country, the demand for vaccines for pneumococcal diseases is growing. Pneumococcal diseases, caused by the bacterium Streptococcus pneumoniae, can lead to severe illnesses such as pneumonia, meningitis, and bloodstream infections. These diseases pose a considerable burden on the healthcare system in Australia, leading to hospitalisations and, in some cases, fatalities. Certain populations, such as infants, young children, the elderly, and individuals with certain underlying medical conditions, are more susceptible to pneumococcal infections. The demand for pneumococcal vaccines is particularly high among these high-risk groups. The Australian government and public health authorities recognise the importance of preventing pneumococcal diseases. They have implemented vaccination programmes and campaigns to increase awareness and vaccine coverage. Pneumococcal vaccines are typically included in Australia's childhood immunisation schedule. Infants and young children receive pneumococcal vaccinations as part of their routine vaccinations to provide early protection against these diseases.

According to the report, types are segmented into multivalent vaccines and monovalent vaccines. Among them, multivalent vaccines are the leading market. Multivalent vaccines combine protection against multiple diseases into a single vaccine, reducing the number of shots needed. This simplification is particularly advantageous for children and adolescents, as it minimises the discomfort and inconvenience associated with multiple injections. Australia's strong commitment to vaccination has led to high vaccine coverage rates among the population. The use of combination vaccines in routine immunisation programmes helps maintain and improve vaccine coverage. Australia's strong commitment to vaccination has led to high vaccine coverage rates among the population. The use of combination vaccines in routine immunisation programmes helps maintain and improve vaccine coverage. The Australian government actively supports and promotes the use of combination vaccines as part of its public health initiatives. This support includes funding for vaccine procurement and distribution. Australia aligns its vaccination policies with international recommendations from organisations like the World Health Organisation (WHO) and the Pan American Health Organisation (PAHO). These organisations often advocate for the use of combination vaccines to improve vaccination coverage.

Based on the distribution channel, it includes hospitals and pharmacies, retail pharmacies, intuitional sales, and others. In Australia, retail pharmacies are contributing significantly to the market share. Retail pharmacies offer convenient access to healthcare products and services, including prescription medications, over-the-counter drugs, and vaccines. They are often located in easily accessible areas, making it convenient for people to fill prescriptions and access healthcare advice. Retail pharmacies often provide medication adherence programmes, helping patients understand and adhere to their prescribed treatment plans. This leads to better health outcomes and reduces healthcare costs associated with non-adherence. Many retail pharmacies offer vaccination services, including flu shots and travel vaccines. This accessibility encourages people to stay up-to-date with their vaccinations, contributing to public health goals. Retail pharmacies have embraced technology, offering online prescription ordering, telepharmacy services, and digital health platforms that allow patients to access health information and services remotely.

Considered in this report:
• Geography: Australia
• Historic year: 2017
• Base year: 2022
• Estimated year: 2023
• Forecast year: 2028

Aspects covered in this report:
• Australia Vaccines market Outlook with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Technology
• Conjugate vaccines
• Inactivated & Subunit vaccines
• Live Attenuated vaccines
• Recombinant vaccines
• Toxoid vaccines
• Viral vector vaccines
• Others

By Route of Administration
• Intramuscular and Subcutaneous Administration
• Oral Administration
• Others

By Disease
• Rotavirus
• Pneumococcal diseases
• Cancer
• Influenza
• Diphtheria, Pertussis, and Tetanus (DTP)
• Human Papilloma Virus (HPV)
• Hepatitis
• Shingles
• Meningococcal diseases
• Varicella (Chicken Pox)
• Mumps
• Others

By Type
• Multivalent vaccines
• Monovalent vaccines

By End-User Type
• Paediatrics
• Adults

By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

The approach of the report:
This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and list out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, and annual reports of companies, analyzing the government-generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers into regional aspects, tier aspects, age groups, and gender. Once we have primary data with us we started verifying the details obtained from secondary sources.

Intended audience:
This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to the Drone industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.

ページTOPに戻る

Table of Contents